

Kinea Bio, Inc, kineabio.com, founded 2020, private company, HQ: Seattle WA, Series A funding sought, \$20M round, please contact: Martin K. (Casey) Childers, DO, PhD (CEO), casey@kineabio.com

Keywords: pre-clinical, neuromuscular diseases, gene therapy, Duchenne muscular dystrophy (DMD), congenital muscular dystrophy (CMD), Myotonic dystrophy type 1 (DM1), dysferlinopathy, Duchenne cardiomyopathy, accelerated development

Kinea Bio was founded by leaders in the neuromuscular disease (NMD) space who are driven to accelerate gene therapies for patients. The Kinea platform utilizes next-generation technologies to improve expression, dosing, and gene-size limitations that currently hinder NMD gene therapy. Kinea has clinical pipelines for DMD and congenital muscular dystrophy (FKRP-deficient), and discovery pipelines for DM1, dysferlinopathy, and Duchenne cardiomyopathy. Next industry-changing therapeutics will be developed using Kinea's development engine: creating human cell-based disease models, engineered tissues and *in vitro* functional assays in accordance with the FDA Modernization Act 2.0. This engine can reduce development timelines and costs, and bring life-saving therapeutics to patients who have no available approved treatments.



KINEABIO